17.10.2012 • NewsAbbottQ3 2012pharmaceutical industry

Abbott Q3 Profit Tops View

Abbott Laboratories reported mixed quarterly results, with earnings topping estimates but sales missing expectations as growth slowed for its Humira arthritis drug and other branded medicines and for its nutritional products.

Abbott said on Wednesday it earned $1.94 billion, or $1.21 per share, in the third quarter, compared with $303 million, or 19 cents per share, in the year-earlier period, when the company took a $1.4 billion litigation-related charge.

Excluding special items, Abbott earned $1.30 per share. Analysts, on average, expected $1.28, according to Thomson Reuters I/B/E/S.

Global sales fell 0.4% to $9.77 billion and fell short of Wall Street expectations of $9.93 billion. Sales would have risen 4.1%, if not for a stronger dollar, which lowers the value of sales in overseas markets.

Abbott said it remains on track to spin off its branded drugs business by Jan. 1, 2013 into a publicly traded company called AbbVie.

Abbott narrowed its full-year 2012 profit forecast to $5.06 to $5.08 per share, from an earlier outlook of $5.00 to $5.10.

Sales of Humira, by far its biggest product, rose 10.1% to $2.33 billion - a slowdown from growth of almost 17% in the prior quarter.

Revenue from Abbott's array of patent-protected prescription drugs, which it calls proprietary pharmaceuticals, rose 2.4% to $4.42 billion, while sales of nutritional products rose 4.5% to $1.6 billion. Growth in both categories slowed down from the second quarter.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.